Novartis has broken ground on a purpose-built 46,000 sq. ft. radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking a pivotal step in the Swiss pharmaceutical giant’s $23 billion commitment to expanding its United States research and manufacturing footprint. The $280 million investment represents one of the largest capital project commitments Denton has seen in over a decade. The facility, located in the Dallas-Fort Worth metropolitan area, will become Novartis’ fifth RLT production site in the US and its first manufacturing presence in the state of Texas. Construction is now fully underway, with the site expected to reach operational status in 2028. The groundbreaking ceremony was attended by US Under Secretary of Commerce Jeffrey Kessler, Swiss Ambassador Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, Denton Mayor Gerard Hudspeth, and Novartis leadership. The project is projected to generate between 150 and 175 skilled jobs spanning bioengineering, advanced manufacturing, quality assurance, and operations, cementing North Texas as a node in what Novartis describes as the largest RLT manufacturing network in the United States.

Texas Joins a Coast-to-Coast Network Built for Speed and Precision

The Denton facility carries particular strategic weight within the broader Novartis RLT network because of the time-critical nature of radioligand therapies. Each dose is custom-made from radioisotopes that begin decaying the moment they are produced, meaning that geographic proximity to patients and treatment centers is not simply a convenience but a clinical necessity. The southern United States had previously lacked a dedicated RLT production point, leaving patients in the region reliant on facilities in New Jersey, Indiana, and California. Denton closes that gap decisively. Denton City Council unanimously approved $3.2 million in tax incentives for the project in December 2024, including a 50% real property tax abatement over ten years and a 50% sales tax rebate on construction materials, while two pending state incentives are expected to provide an additional $5.9 million in tax exemptions over a decade. The Denton project sits within a broader wave of pharmaceutical manufacturing investment across Texas and the American South. Bristol Myers Squibb’s radiopharmaceutical facility investments and Eli Lilly’s oncology manufacturing expansions provide context for how the sector is reconfiguring US supply chains around cancer drugs that demand fast, reliable delivery. This same momentum is also evident in Texas’ expanding pediatric oncology infrastructure, including the Kinder Foundation’s US$150 million gift to launch the nation’s largest pediatric cancer center in Houston, highlighting how manufacturing capacity and specialized treatment delivery are being scaled in parallel to meet rising cancer care demand. For a detailed look at similar advanced manufacturing investments in the life sciences sector, the trend points consistently toward decentralised, regionally anchored production models. Novartis’ Denton site is a textbook execution of that logic, placed deliberately inside a rapidly growing Sun Belt population centre with access to a highly educated North Texas workforce.

Project Fact Sheet

• Project Name: Novartis Denton Radioligand Therapy Manufacturing Facility
• Location: Denton, Texas, USA (Dallas-Fort Worth Metropolitan Area)
• Project Value: US$280 million
• Client / Owner: Novartis AG (Swiss Stock Exchange: NOVN.SW)
• Facility Size: 46,000 square feet
• Key Components: Purpose-built RLT manufacturing plant; renovation of existing office and warehouse buildings; new structures for future operations; utility and infrastructure upgrades
• Construction Start: May 2026
• Expected Completion / Operational Date: 2028
• Jobs Created: 150 to 175 permanent positions including process engineers, quality control analysts, and maintenance technicians
• Strategic Impact: Fifth US RLT manufacturing site; first in Texas; closes a southern US supply gap for time-sensitive cancer therapies
• Incentives Approved: $3.2 million in City of Denton tax incentives; approximately $5.9 million in pending state tax exemptions over ten years
• Broader Investment Context: Part of Novartis’ $23 billion, five-year US manufacturing and research expansion plan comprising seven new and three expanded facilities nationwide

Project Team

• Client / Owner: Novartis AG, Basel, Switzerland
• Economic Development Authority: City of Denton Economic Development Department
• Government Representatives: US Department of Commerce; State of Texas (Senator Brent Hagenbuch, Representative Andy Hopper); City of Denton (Mayor Gerard Hudspeth)
• Swiss Government Representative: Swiss Embassy to the United States (Ambassador Ralf Heckner)
• Clinical Partner: Texas Oncology (administering RLT treatments to patients across the region)
• Main Contractor: To be confirmed; likely shortlisted from firms with pharmaceutical manufacturing construction experience such as DPR Construction, Gilbane Building Company, or Barton Malow
• Regulatory Oversight: US Food and Drug Administration (FDA); US Nuclear Regulatory Commission (NRC) for radioactive material handling